[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barzilai Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100584448","liquid-biopsy-assay-of-ebus-tbna-supernatant-fluid-for-diagnosing-lung-cancer-100584448",false,"NCT06889467","Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer","Validation of Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer: A Feasibility Study","Inclusion Criteria:\n\n* adult (age ≥18 years) patients with high suspicion for NSCLC with thoracic lymph nodes involvement (per clinical judgement and imaging studies), planned for an EBUS-TBNA procedure\n* Subjects with negative EBUS-TBNA results (no evidence of lymph node involvement by tumor according to histology) who will require surgical resection of the thoracic lymph nodes will comprise the final study group\n\nExclusion Criteria:\n\n1. Subjects unable or not willing to provide informed consent for study participation.\n2. Subjects in whom NSCLC will ultimately be ruled out.\n3. Subjects who will not require surgical resection of thoracic lymph nodes, or who will not undergo such procedure in our Medical Center for any reason","ALL","18 Years",{"count":19,"type":20},10,"ESTIMATED","OBSERVATIONAL","Background and aim: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the gold standard of lung cancer staging, yet up to 15% of procedures produce inadequate samples for definite diagnosis or staging. In such cases, more invasive surgical procedures are usually considered. Fluid collected during EBUS-TBNA is centrifuged to produce a pellet for cell block histopathological examination , while the supernatant is usually discarded. It has been demonstrated that this supernatant can provide material for next generation sequencing (NGS) mutation analysis using liquid biopsy (LB) technics when the procedure yielded positive results (tumor cells were demonstrated in the aspirate).\n\nWe wish to assess whether LB NGS of the supernatant may provide data regarding lymph nodes involvement in non-small cell lung cancer (NSCLC) in cases with a negative EBUS-TBNA evaluation (no tumor cell identified in the aspirate).\n\nMethods: A prospective feasibility study which will recruit participants with high suspicion for thoracic lymph nodes involvement in NSCLC who will be subjected to EBUS-TBNA. The final study group will comprise of 10 subjects with a negative EBUS-TBNA evaluation (no tumor cell detected) who will require surgical resection of the thoracic lymph nodes.\n\nEBUS-TBNA collected fluid will be centrifuged and separated. Cellular pellets will undergo cytological and histopathological evaluation, including tissue NGS, as usual. Cell-free DNA will be extracted from the supernatant and will undergo separate LB NGS targeted to genes frequently mutated in NSCLC. We will assess the concordance between the positivity of supernatant NGS and surgical lymph nodes staging, and the concordance between supernatant NGS and blood NGS.\n\nExpected results: We expect high concordance between surgical lymph nodes staging and supernatant NGS, that is, genetic mutations would be identified by the supernatant NGS in subjects with lymph nodes involvement by tumor, and not in those without it.\n\nImportance to Medicine: NSCLC is the leading cause of cancer mortality. Improving the effectiveness of EBUS-TBNA may reduce the need for additional invasive procedures, increase accuracy and reduce turnaround time of specimens.",[24,25,26,27,28],"Non Small Cell Lung Cancer","Non Small Cell Lung Cancer (NSCLC)","Lung Cancer (NSCLC)","Lung Cancer - Non Small Cell","Pulmonary Nodule",[30,31,32,33,34,35,36,37],"Endobronchial ultrasound","Endobronchial ultrasound transcbronchial needle aspiration","EBUS","EBUS-TBNA","staging","lung cancer","non small cell lung cancer","NSCLC","RECRUITING","2025-03-22",{"date":41,"type":42},"2025-03-26","ACTUAL",{"date":44,"type":42},"2025-01-20",{"date":46,"type":20},"2025-12-31",{"name":48,"class":49},"Barzilai Medical Center","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100328775","efficacy-of-metoclopramide-in-poor-ovarian-response-ivf-patients-100328775","NCT03560583","Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients","Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Poor response according to \"Bologna criteria\"\n\nExclusion Criteria:\n\n* Allergy to metoclopramide\n* Prolactinemia\n* Women treated with dopamine agonists",true,"FEMALE","54 Years",{"count":62,"type":20},60,"INTERVENTIONAL",[65],"NA","Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.\n\nMetoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.\n\nThe mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.",[68],"Poor Responders in IVF","2025-02-06",{"date":71,"type":42},"2025-02-10",{"date":73,"type":42},"2021-05-05",{"date":75,"type":20},"2028-07",{"name":48,"class":49},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":63,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":99,"leadSponsor":101,"locationsCount":50},"100575545","evaluating-the-effectiveness-of-using-a-home-laser-device-to-treat-patients-with-knee-osteoarthritis-100575545","NCT06773676","Evaluating the Effectiveness of Using a Home Laser Device to Treat Patients With Knee Osteoarthritis","Evaluation of the Efficacy of a Home-Use Photobiomodulation Device for the Treatment of Patients With Knee Osteoarthritis: A Double-Blind, Randomized, Sham-Controlled Clinical Study","Inclusion Criteria:\n\n1. Diagnoses of knee osteoarthritis by American College of Rheumatology (ACR)\n2. Kellgren \\& Lawrence classification 1-3\n3. Knee pain on movement 40 to 90 mm Visual Analog Scale\n4. Knee pain and related functional reduction for at least 1 month\n\nExclusion Criteria:\n\n1. Pregnant or nursing, or with the ability to become pregnant and not using an accepted form of birth control\n2. Other causes of knee-related pain (e.g. hip OA, arterial insufficiency, radiculopathy etc) have been ruled out by physical examinations.\n3. Knee surgery for KOA\n4. Intra-articular steroid injection and\u002For oral steroid treatment within the last six months\n5. Rheumatoid arthritis\n6. Symptomatic OA in other joints (i.e. hip, hand)\n7. Use of narcotics on the day of evaluation\n8. Active malignancy\n9. Uncontrolled diabetes mellitus\n10. Neurological conditions: sciatica, neuropathy, multiple sclerosis\n11. Other chronic pain conditions that may affect results: Fibromyalgia, back pain, hip pain\n12. Has any photobiomodulation (low level laser) device at home or has previously used photobiomodulation for knee pain\n13. Has known dermatological sensitivity to light\n14. Enrolled in any other clinical trial within the last 6 weeks or enrollment in another clinical trial during participation in this trial.","50 Years","90 Years",{"count":87,"type":20},50,[65],"Osteoarthritis is a degenerative disease affecting joint cartilage and its surrounding tissue. It is the leading cause of disability in the elderly. Photobiomodulation (PBM), has been used widely for alleviation of pain, reduction of inflammation, and acceleration of wound healing, and particularly to treat knee osteoarthritis (KOA). The purpose of the current study is to determine if a near-infrared PBM device (B-Cure Laser), applied at home, by the patient or personal caregiver in a real-life situation, can reduce pain and improve functionality in patients with KOA.",[91],"Osteoarthritis Of Knee",[93,94],"Osteoarthritis","Knee Osteoarthritis","2025-01-13",{"date":97,"type":42},"2025-01-14",{"date":97,"type":20},{"date":100,"type":20},"2027-01-31",{"name":48,"class":49},""]